Article Text

Download PDFPDF

Original research
Neuroform Atlas Stent System for the treatment of intracranial aneurysm: primary results of the Atlas Humanitarian Device Exemption cohort
  1. Brian T Jankowitz1,
  2. Ricardo Hanel2,
  3. Ashutosh P Jadhav3,
  4. David N Loy4,
  5. Donald Frei5,
  6. Adnan H Siddiqui6,
  7. Ajit S Puri7,
  8. Ahmad Khaldi8,
  9. Aquilla S Turk9,
  10. Adel M Malek10,
  11. Eric Sauvageau2,
  12. Steven W Hetts11,
  13. Osama O Zaidat12
  1. 1 Department of Neurological Surgery, UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, USA
  2. 2 Lyerly Neurosurgery, Jacksonville, Florida, USA
  3. 3 Department of Neurology, UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, USA
  4. 4 Radiology, University of Virginia, Richmond, Virginia, USA
  5. 5 Department of Radiology, Swedish Medical Center, Denver, Colorado, USA
  6. 6 University at Buffalo Neurosurgery, Buffalo, New York, USA
  7. 7 Department of Radiology, University of Massachusetts, Worcester, Massachusetts, USA
  8. 8 Neurosurgery at WellStar Kennestone Hospital, Medical University of South Carolina, Charleston, South Carolina, USA
  9. 9 Department of Radiology, Medical University of South Carolina, Charleston, South Carolina, USA
  10. 10 Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts, USA
  11. 11 Interventional Neuroradiology, The University of California San Francisco, San Francisco, California, USA
  12. 12 Neuroscience Department, Bon Secours Mercy Health St Vincent Medical Center, Toledo, USA
  1. Correspondence to Dr. Osama O Zaidat, Neuroscience Department, Bon Secours Mercy Health St Vincent Medical Center, Toledo, OH 43608, USA; OOZaidat{at}


Background and objective Stent-assisted coil embolization is a well-established treatment of intracranial wide-necked aneurysms. The Neuroform Atlas Stent System is a new generation microstent designed to enhance coil support, conformability, deliverability, and improve deployment accuracy. We present the 1-year efficacy and angiographic results of the Humanitarian Device Exemption (HDE) cohort from the Atlas Investigational Device Exemption (IDE) clinical trial.

Method The Atlas IDE trial is a prospective, multicenter, single-arm, open-label study of unruptured wide-necked intracranial aneurysms treated with the Neuroform Atlas stent and approved coils. The primary efficacy endpoint was the rate of 12-month complete aneurysm angiographic occlusion (Raymond class I) without target aneurysm retreatment or significant parent artery stenosis (>50%) at the target location. The primary safety endpoint was the rate of major ipsilateral stroke or neurological death within 12 months. Imaging core laboratory and Clinical EventsCommittee adjudicated the primary endpoints.

Results 30 patients were enrolled at eight US centers, with 27 patients completing the 12-month angiographic follow-up. The mean age was 59.4±11.8 years and 24/30 patients (80%) were women. The mean aneurysm size was 5.3±1.7 mm and the dome:neck ratio was 1.1±0.2. Procedural technical success of Neuroform Atlas Stent deployment was 100%. 27 patients completed 12-month angiographic follow-up and 30 patients completed their 6-month follow-up. When applying the last observation carried forward method, the primary efficacy endpoint was observed in 26/30 patients (86.7%, 95% CI 69.3% to 96.2%) compared with 25/27 patients (92.6%, 95% CI 75.7% to 99.1%) who completed the 12-month angiographic follow-up. The primary safety endpoint of stroke occurred in one patient (3.3%), who made a complete clinical recovery at discharge. There were no neurological deaths.

Conclusion The Neuroform Atlas stent in conjunction with coils demonstrated a high rate of complete aneurysm occlusion at 12-month angiographic follow-up, with an improved safety profile in the HDE cohort.

Clinical registration number NCT0234058;Results

  • atlas stent
  • cerebral aneurysm
  • stent-assisted coiling
  • neuroform
  • wide-neck aneurysm

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • BTJ and OOZ contributed equally.

  • Contributors All authors contributed to the final draft with revisions, edits, and contents and also participated in enrolling subjects.

  • Funding This work was sponsored by Stryker Neurovascular, Fremont, California, USA.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.